Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy
Authors
Keywords
-
Journal
ACTA ONCOLOGICA
Volume -, Issue -, Pages 1-9
Publisher
Informa UK Limited
Online
2019-01-14
DOI
10.1080/0284186x.2018.1556804
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial
- (2018) Timothy J Iveson et al. LANCET ONCOLOGY
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
- (2018) Axel Grothey et al. NEW ENGLAND JOURNAL OF MEDICINE
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Oxaliplatin added to fluoropyrimidine for adjuvant treatment of colorectal cancer is associated with long-term impairment of peripheral nerve sensory function and quality of life
- (2016) Måns Stefansson et al. ACTA ONCOLOGICA
- Peripheral neuropathy in colorectal cancer survivors: The influence of oxaliplatin administration. Results from the population-based PROFILES registry
- (2015) Antoinetta J. M. Beijers et al. ACTA ONCOLOGICA
- Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer
- (2015) Dimitrios Pectasides et al. BMC CANCER
- Neuropathic Symptoms and Their Risk Factors in Medical Oncology Outpatients With Colorectal vs. Breast, Lung, or Prostate Cancer: Results From a Prospective Multicenter Study
- (2015) Mark A. Lewis et al. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
- Bevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab
- (2014) Jim Zhong et al. CANCER
- Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity?
- (2014) L.M. Soveri et al. EUROPEAN JOURNAL OF CANCER
- Advances in the management of colorectal cancer: from biology to treatment
- (2014) Shahid Ahmed et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
- A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration
- (2014) A. J. M. Beijers et al. SUPPORTIVE CARE IN CANCER
- Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing
- (2013) K E Caudle et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Chemotherapy-Induced Neuropathy and Its Association With Quality of Life Among 2- to 11-Year Colorectal Cancer Survivors: Results From the Population-Based PROFILES Registry
- (2013) Floortje Mols et al. JOURNAL OF CLINICAL ONCOLOGY
- Oxaliplatin-induced peripheral neuropathy’s effects on health-related quality of life of colorectal cancer survivors
- (2013) Cindy Tofthagen et al. SUPPORTIVE CARE IN CANCER
- Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis
- (2013) Jun Cai et al. World Journal of Surgical Oncology
- Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01
- (2012) Kelley M. Kidwell et al. CANCER
- Intrapatient Cetuximab Dose Escalation in Metastatic Colorectal Cancer According to the Grade of Early Skin Reactions: The Randomized EVEREST Study
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup
- (2011) Anne McTiernan et al. EUROPEAN JOURNAL OF CANCER
- Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer
- (2011) Daniel G. Haller et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-Term Neuropathy After Oxaliplatin Treatment: Challenging the Dictum of Reversibility
- (2011) S. B. Park et al. ONCOLOGIST
- Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer
- (2010) Michel Ducreux et al. INTERNATIONAL JOURNAL OF CANCER
- Persistent neuropathy after treatment with cisplatin and oxaliplatin
- (2009) Elke E. M. Brouwers et al. ACTA ONCOLOGICA
- Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
- (2009) Thierry André et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now